BMO Capital Markets restated their outperform rating on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a report released on Wednesday, July 26th. BMO Capital Markets currently has a $13.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $12.00.
A number of other brokerages also recently weighed in on TTPH. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a buy rating and a $15.00 price objective for the company. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, July 6th. Finally, Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and upped their price objective for the stock from $8.00 to $15.00 in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $10.25.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up 0.5301% during trading on Wednesday, hitting $5.6699. The stock had a trading volume of 558,095 shares. The firm has a 50-day moving average price of $7.40 and a 200 day moving average price of $6.92. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The company’s market capitalization is $289.47 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same period in the previous year, the company posted ($0.47) earnings per share. Tetraphase Pharmaceuticals’s revenue for the quarter was up 28.2% compared to the same quarter last year. Equities analysts anticipate that Tetraphase Pharmaceuticals will post ($2.65) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals’ (TTPH) Outperform Rating Reiterated at BMO Capital Markets” was originally posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/08/bmo-capital-markets-reaffirms-outperform-rating-for-tetraphase-pharmaceuticals-inc-ttph-updated.html.
A number of hedge funds have recently added to or reduced their stakes in TTPH. Russell Investments Group Ltd. acquired a new stake in Tetraphase Pharmaceuticals during the fourth quarter worth approximately $156,000. Bank of New York Mellon Corp boosted its stake in Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after buying an additional 6,114 shares during the period. State Street Corp boosted its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares during the period. GSA Capital Partners LLP boosted its stake in Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 15,931 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Tetraphase Pharmaceuticals by 580.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 226,222 shares of the biopharmaceutical company’s stock valued at $912,000 after buying an additional 192,972 shares during the period. Institutional investors own 35.76% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.